A new report says that London is the top city in Europe for the life sciences industry, and ranks third worldwide after Boston and New York in the US. That puts the city above some well-recognised ...
The promise of AI in pharma is sprouting up across the business, from marketing to manufacturing to R&D. But one of the most game-changing areas – and one in which we've seen billions of dollars ...
Adcendo has tapped into the strong investor appetite for companies developing antibody-drug conjugates for cancer with an ...
Today, 36 million people in the European Union (EU) and 30 million in the US with a rare disease face the harsh reality of a ...
Sanofi has officially opened a modular biologics manufacturing facility in Singapore that is designed to allow rapid ...
The first company to take up residence in Bayer Co.Lab Berlin – initially located on the group's pharma headquarters site in ...
A strategy for women's health in England was published in 2022 under the previous Conservative government, led at the time by ...
Kelun-Biotech has become the second drugmaker to bring a TROP2-directed antibody-drug conjugate to regulatory approval, ...
A high-tech device that can monitor medication use and compliance has been cleared by the FDA for use with AstraZeneca’s Airsupra and Breztri inhalers. Developed by Australian medtech firm ...
Aviv Regev, executive vice president and head of Genentech Research & Early Development (gRED) NVIDIA’s push into the life sciences sector has been rewarded by a wide-ranging deal with Roche’s ...
AstraZeneca’s legal challenge to Medicare’s drug pricing negotiation powers has stumbled at the first hurdle in a federal court. US judge Colm Connolly of US district court in Delaware ...
Eli Lilly has said it is prepared to invest £279 million ($364 million) in the UK and work with the government to tackle serious public health challenges, including obesity. The proposal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback